Sera Prognostics Inc (SERA) — Titan Protect Analysis

SERA

Sera Prognostics Inc

Healthcare · ·

$2.29

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$80M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-2.98

Based on estimated future earnings — lower means cheaper

Rev Growth

-63.2%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-39.6%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$5.00

+118% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 1 analysts covering this stock

About Sera Prognostics Inc

Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy relate

https://www.sera.com

Country: United States Employees: 71 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

-0.149

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0405

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.601

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-50.0%

Historical annualised return based on price data

Max Drawdown

-83.3%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

214

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.93

Less volatile than the market — more defensive

52W High

$4.09

44% below the year high

52W Low

$1.37

67% above the year low

Avg Volume

68,844

Average daily shares traded — higher means easier to buy and sell

Short Ratio

7.0

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.64

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

3.71

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

-191.2%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-66,857.1%

Profit from core operations before interest and tax

Free Cash Flow

$-18,903,124

Negative — the business is spending more than it generates

Revenue (TTM)

$57,000

Total revenue over the last 12 months

Net Income

$-32,140,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$5.00

Target Median

$5.00

Target Low

$5.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go